Clinical characteristics and risk factors of hepatitis B virus-related cirrhosis/hepatocellular carcinoma: A single-center retrospective study

被引:5
作者
Chen, Feng [1 ,2 ]
Li, Qianhui [1 ]
Xu, Xiaomin [1 ]
Wang, Fei [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 7, Div Gastroenterol, Shenzhen, Guangdong, Peoples R China
[2] Third Peoples Hosp Shenzhen, Natl Clin Res Ctr Infect Dis, Shenzhen, Guangdong, Peoples R China
关键词
Alanine aminotransferase (ALT); Hepatitis B virus (HBV); Liver cirrhosis (LC); Hepatocellular carcinoma (HCC); Risk factors; HEPATOCELLULAR-CARCINOMA; DIAGNOSIS; PROGRESSION; MORTALITY;
D O I
10.1016/j.livres.2023.07.004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: Hepatitis B virus (HBV) infection is a major global health problem which progresses to liver cirrhosis (LC) and hepatocellular carcinoma (HCC). Early prediction of disease changes and intervention are essential to slow disease progression and protect liver function. This study aimed to analyze the clinical characteristics of patients with HBV-related LC and HCC at different serum alanine aminotransferase (ALT) levels and explore the risk factors of HBV infection progressing to LC/HCC.Methods: A total of 379 patients with HBV infection treated in The Third People's Hospital of Shenzhen between January 2014 and December 2016 without any antiviral drug therapy were enrolled. Patients were divided into the LC/HCC and non-LC/HCC groups based on clinical diagnosis, which was determined through imaging and expressions of pathological and laboratory test markers, and patients with LC/HCC were further divided into three groups according to the serum ALT levels. Differences in general information, clinical symptoms, and expression levels of serological indices of the above groups were compared and analyzed, logistic regression was used to analyze the risk factors for LC/HCC development, and the clinical diagnostic efficacy of indicators was judged by the receiver operator characteristic (ROC). Results: LC/HCC mainly occurred in the ALT normal and mildly elevated groups, with 70.83% of patients with HCC having an LC background. In the comparison of different ALT level groups, the moderately -severely elevated group had the highest proportion of patients with skin jaundice, abdominal varices, rebound tenderness, higher white blood cell and neutrophil (NEUT) counts; and higher levels of aspartate aminotransferase, glutamyl transpeptidase, total bilirubin, and direct bilirubin. The LC/HCC group was older and had significantly higher proportions of male patients, alcohol consumption, and combined hypertension than the non-LC/HCC group (all P < 0.05). Logistic regression analysis showed that age, combined hypertension, abdominal varicose veins, subcostal palpation, and NEUT count were risk factors for LC/HCC development; and the area under the curve for this model on the ROC analysis was 0.935 (95% confidence interval 0.899-0.972) with specificity and sensitivity of 97.4% and 70.7%, respectively. Conclusions: Advanced age, combined hypertension, abdominal varicose veins, subcostal palpation, and high NEUT count are risk factors for LC/HCC development in patients with untreated HBV infection.(c) 2023 The Third Affiliated Hospital of Sun Yat-sen University. Publishing services by Elsevier B. V. on behalf of KeAi Communications Co., Ltd.
引用
收藏
页码:237 / 243
页数:7
相关论文
共 22 条
  • [1] Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related Death
    Chen, Jin-De
    Yang, Hwai-I
    Iloeje, Uchenna H.
    You, San-Lin
    Lu, Sheng-Nan
    Wang, Li-Yu
    Su, Jun
    Sun, Chien-An
    Liaw, Yun-Fan
    Chen, Chien-Jen
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : 1747 - U38
  • [2] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
    Lampertico P.
    Agarwal K.
    Berg T.
    Buti M.
    Janssen H.L.A.
    Papatheodoridis G.
    Zoulim F.
    Tacke F.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 67 (02) : 370 - 398
  • [3] AASLD guidelines for the treatment of hepatocellular carcinoma
    Heimbach, Julie K.
    Kulik, Laura M.
    Finn, Richard S.
    Sirlin, Claude B.
    Abecassis, Michael M.
    Roberts, Lewis R.
    Zhu, Andrew X.
    Murad, M. Hassan
    Marrero, Jorge A.
    [J]. HEPATOLOGY, 2018, 67 (01) : 358 - 380
  • [4] Progression to cirrhosis, hepatocellular carcinoma and liver- related mortality in chronic hepatitis B patients in Italy
    Ieluzzi, Donatella
    Covolo, Loredana
    Donato, Francesco
    Fattovich, Giovanna
    [J]. DIGESTIVE AND LIVER DISEASE, 2014, 46 (05) : 427 - 432
  • [5] Cellular senescence and hepatitis B-related hepatocellular carcinoma: An intriguing link
    Karakousis, Nikolaos D.
    Papatheodoridi, Alkistis
    Chatzigeorgiou, Antonios
    Papatheodoridis, George
    [J]. LIVER INTERNATIONAL, 2020, 40 (12) : 2917 - 2927
  • [6] Current epidemiology in hepatocellular carcinoma
    Konyn, Peter
    Ahmed, Aijaz
    Kim, Donghee
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 15 (11) : 1295 - 1307
  • [7] Epidemiology and Management of Hepatocellular Carcinoma
    Kulik, Laura
    El-Serag, Hashem B.
    [J]. GASTROENTEROLOGY, 2019, 156 (02) : 477 - +
  • [8] Diagnosis of Chronic Hepatitis B Pericomplication: Risk factors and Trends Over Time
    Lapointe-Shaw, Lauren
    Chung, Hannah
    Holder, Laura
    Kwong, Jeffrey C.
    Sander, Beate
    Austin, Peter C.
    Janssen, Harry L. A.
    Feld, Jordan J.
    [J]. HEPATOLOGY, 2021, 73 (06) : 2141 - 2154
  • [9] Trends and Age-Period-Cohort Effects on the Prevalence, Incidence and Mortality of Hepatocellular Carcinoma from 2008 to 2017 in Tianjin, China
    Liu, Chengyu
    Wu, Jing
    Chang, Zheng
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (11)
  • [10] Liver Cancer Study Group Chinese Society of Hepatology Chinese Medical Association, 2021, Zhonghua Gan Zang Bing Za Zhi, V29, P948, DOI 10.3760/cma.j.cn501113-20210907-00456